AI assistant
aTYR PHARMA INC — Director's Dealing 2021
Feb 9, 2021
34337_dirs_2021-02-09_c41d7549-bec8-4e7b-a944-c4695dca6de2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2021-02-06
Reporting Person: Broadfoot Jill Marie (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-06 | Common stock | M | 892 | — | Acquired | 10223 | Direct |
| 2021-02-09 | Common stock | S | 390 | $7.66 | Disposed | 9833 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-06 | Restricted Stock Unit | $ | M | 892 | Disposed | Common Stock (892) | Direct |
Footnotes
F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: Includes 178 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 16, 2020.
F4: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019.
F5: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020.